OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis $0.02 +0.00 (+3.33%) As of 10/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Mateon Therapeutics Stock (OTCMKTS:MATN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mateon Therapeutics alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0452-Week Range$0.13▼$0.38Volume107,654 shsAverage Volume338,444 shsMarket Capitalization$1.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mateon Therapeutics, Inc. is a biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research has centered on treatments designed to target tumor blood vessels and disrupt the vascular systems that support cancer growth. Mateon’s development programs have included OXi4503, an investigational vascular-disrupting agent derived from combretastatin technology. The compound has been studied for potential use in oncology indications, including acute myeloid leukemia and solid tumors. The company has also explored additional therapeutic applications and programs in response to emerging medical needs. Mateon Therapeutics was formerly known as OXiGENE, Inc. and adopted its current name as its business strategy evolved. Publicly available information about its current operations, leadership, geographic reach and commercial products is limited, and its programs remain primarily development-stage rather than marketed therapies.AI Generated. May Contain Errors. Read More Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MATN Stock News HeadlinesSorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummaryFebruary 25, 2023 | benzinga.comSee More Headlines MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed this year? Mateon Therapeutics' stock was trading at $0.0784 at the start of the year. Since then, MATN stock has decreased by 72.3% and is now trading at $0.0217. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) issued its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), BioLineRx (BLRX). Company Calendar Last Earnings5/15/2019Today10/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year Founded1996Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.11Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$1.96 million OptionableNot Optionable Beta1.33 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:MATN) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mateon Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
